Mechanisms of C1-inhibitor deficiency

Immunobiology

Volumn 205, Issue 4-5, 2002, Pages 542-551

  Pappalardo, Emanuela ^a   Zingale, Lorenza C ^a   Terlizzi, Adelaide ^a   Zanichelli, Andrea ^a   Folcioni, Anna ^a   Cicardi, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BRADYKININ; COMPLEMENT COMPONENT C1; COMPLEMENT INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ANGIONEUROTIC EDEMA; BLOOD VESSEL PERMEABILITY; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; GENE MUTATION; GENE STRUCTURE; INTESTINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SEPSIS; SKIN; UPPER RESPIRATORY TRACT;

EID: 0036747263     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00153     Document Type: Article

References (51)

1. SILVERMAN, G. A., P. I. BIRD, R. W. CARRELL, F. C. CHURCH, P. B. COUGHLIN, P. G. GETTINS, J. A. IRVING, D. A. LOMAS, C. J. LUKE, R. W. MOYER, P. A. PEMBERTON, E. REMOLD-O'DONNELL, G. S. SALVESEN, J. TRAVIS, and J. C. WHISSTOCK. 2001. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276: 33293.
2. IRVING, J. A., R. N. PIKE, A. M. LESK, and J. C. WHISSTOCK. 2000. Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res. 10: 1845.
3. HOPKINS, P. C., R. W. CARRELL, and S. R. STONE. 1993. Effects of mutations in the hinge region of serpins. Biochemistry 32: 7650.
4. WHISSTOCK, J. C., R. N. PIKE, L. JIN, R. SKINNER, X. Y. PEI, R. W. CARRELL, and A. M. LESK. 2000. Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparindagger. J. Mol. Biol. 301: 1287.
5. STEIN, P. E., and R. W. CARRELL. 1995. What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2: 96.
6. JANCIAUSKIENE, S. 2001. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim. Biophys. Acta 1535: 221.
7. CARRELL, R. W., and D. A. LOMAS. 2002. Alpha 1-antitrypsin deficiency - a model for conformational diseases. N. Engl. J. Med. 346: 45.
8. DAVIS, A. E. 1988. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 6: 595.
9. Rossi, V., S. CSEH, I. BALLY, N. M. THIELENS, J. C. JENSENIUS, and G. J. ARLAUD. 2001. Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2. J. Biol. Chem. 29: 29.
10. CUGNO, M., I. BOS, Y. LUBBERS, C. E. HACK, and A. AGOSTONI 2001. In vitro interaction of C1-inhibitor with thrombin. Blood Coagul. Fibrinolysis 12: 253.
11. NUSSBERGER, J., M. CUGNO, C. AMSTUTZ, M. CICARDI, A. PELLACANI, and A. AGOSTONI. 1998. Plasma bradykinin in angio-oedema. Lancet 351: 1693.
12. ZAHEDI, R., J. WISNIESKI, and A. E. DAVIS. 1997. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases. J. Immunol. 159: 983.
13. CICARDI, M., L. BERGAMASCHINI, M. CUGNO, A. BERETTA, L. C. ZINGALE, M. COLOMBO, and A. AGOSTONI. 1998. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology 199: 366.
14. HAUERT, J., P. A. PATSTON, and M. SCHAPIRA. 2000. C1 inhibitor cross-linking by tissue transglutaminase. J. Biol. Chem. 275: 14558.
15. JOHNSON, A. M., C. A. ALPER, F. S. ROSEN, and J. M. CRAIG. 1971. C1 inhibitor: evidence for decreased hepatic synthesis in hereditary angioneurotic edema. Science 173: 553.
16. YEUNG LAIWAH, A. C., L. JONES, A. O. HAMILTON, and K. WHALEY. 1985. Complement-subcomponent-C1-inhibitor synthesis by human monocytes. Biochem. J. 226: 199.
17. KATZ, Y., and R. C. STRUNK. 1989. Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J. Immunol. 142: 2041.
18. SCHMAIER, A. H., S. C. MURRAY, G. D. HEDA, A. FARBER, A. KUO, MCCRAE, K., and D. B. CINES. 1989. Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J. Biol. Chem. 264: 18173.
19. SCHMAIER, A. H., S. AMENTA, T. XIONG, G. D. HEDA, and A. M. GEWIRTZ. 1993. Expression of platelet C1 inhibitor. Blood 82: 465.
20. ELLISON, R., S. MASON, P. KOHLER, J. CURD, and L. RELLER. 1986. Meningococcemia and acquired complement deficiency. Association in patients with hepatic failure. Arch. Intern. Med. 146: 1539.
21. DONALDSON, V. H., and R. R. EVANS. 1963. A Biochemical Abnormality in Herediatry Angioneurotic Edema: Absence of Serum Inhibitor of C′ 1-Esterase. Am. J. Sci. 31: 37.
22. BOCK, S. C., K. SKRIVER, E. NIELSEN, H. C. THOGERSEN, B. WIMAN, V. H. DONALDSON, R. L. EDDY, J. MARRINAN, E. RADZIEJEWSKA, R. HUBER, and et al. 1986. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25: 4292.
23. DAVIS, A. E., A. S. WHITEHEAD, R. A. HARRISON, A. DAUPHINAIS, G. A. BRUNS, M. CICARDI, and F. S. ROSEN. 1986. Human inhibitor of the first component of complement, C1: characterization of cDNA clones and localization of the gene to chromosome 11. Proc. Natl. Acad. Sci. USA 83: 3161.
24. TOSI, M., C. DUPONCHEL, P. BOURGAREL, M. COLOMB, and T. MEO. 1986. Molecular cloning of human C1 inhibitor: sequence homologies with alpha 1-antitrypsin and other members of the serpins superfamily. Gene 42: 265.
25. STOPPA-LYONNET, D., M. TOSI, J. LAURENT, A. SOBEL, G. LAGRUE, and T. MEO. 1987. Altered C1 inhibitor genes in type I hereditary angioedema. N. Engl. J. Med. 317: 1.
26. CICARDI, M., T. IGARASHI, M. S. KIM, D. FRANGI, A. AGOSTONI, and A. E. DAVIS. 1987. Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema. J. Clin. Invest. 80: 1640.
27. BOWEN, B., J. J. HAWK, S. SIBUNKA, S. HOVICK, and J. M. WEILER. 2001. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin. Immunol. 98: 157.
28. ROSEN, F., S., J. PENSKY, V. DONALDSON, and P. CHARACHE. 1965. Hereditary Angioneurotic Edema: Two Genetic Variants. Science 148: 957.
29. Tosi, M. 1998. Molecular genetics of C1 inhibitor. Immunobiology 199: 358.
30. PARAD, R. B., J. KRAMER, R. C. STRUNK, F. S. ROSEN, and A. E. DAVIS. 1990. Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site. Proc. Natl. Acad. Sci. USA 87: 6786.
31. ARIGA, T., T. IGARASHI, N. RAMESH, R. PARAD, M. CICARDI, and A. E. DAVIS. 1989. Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon. J. Clin. Invest. 83: 1888.
32. FRANGI, D., M. CICARDI, A. SICA, F. COLOTTA, A. AGOSTONI, and A. E. DAVIS. 1991. Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema. J. Clin. Invest. 88: 755.
33. FRANGI, D., K. S. AULAK, M. CICARDI, R. A. HARRISON, and A. E. DAVIS. 1992. A dysfunctional C1 inhibitor protein with a new reactive center mutation (Arg-444→Leu). FEBS Lett. 301: 34.
34. PAPPALARDO, E., M. CICARDI, C. DUPONCHEL, A. CARUGATI, S. CHOQUET, A. AGOSTONI, and M. TOSI. 2000. Frequent de novo mutations and exon deletions in the c1 inhibitor gene of patients with angioedema. J. Allergy Clin. Immunol. 106: 1147.
35. CICARDI, M., T. IGARASHI, F. S. ROSEN, and A. E. DAVIS. 1987. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J. Clin. Invest. 79: 698.
36. LAPPIN, D. F., MCPHADEN, A. R., P. L. YAP, P. E. CARTER, G. D. BIRNIE, J. E. FOTHERGILL, and K. WHALEY. 1989. Monocyte C1-inhibitor synthesis in patients with C1-inhibitor deficiency. Eur. J. Clin. Invest. 19: 45.
37. KRAMER, J., F. S. ROSEN, H. R. COLTEN, K. RAJCZY, and R. C. STRUNK. 1993. Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. J. Clin. Invest. 91: 1258.
38. VERPY, E., COUTURE-TOSI, E., E. ELDERING, LOPEZ-TRASCASA, M., P. SPATH, T. MEO, and M. TOSI. 1995. Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function. J. Clin. Invest. 95: 350.
39. JACKSON, J., R. B. SIM, A. WHELAN, and C. FEIGHERY. 1986. An IgG autoantibody which inactivates C1-inhibitor. Nature 323: 722.
40. CALDWELL, J. R., S. RUDDY, P. H. SCHUR, and K. F. AUSTEN. 1972. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin. Immunol. Immunopathol. 1: 39.
41. ALSENZ, J., J. D. LAMBRIS, K. BORK, and M. LOOS. 1989. Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1 INH autoantibodies. J. Clin. Invest. 83: 1794.
42. D'INCAN, M., A. TRIDON, D. PONARD, DUMESTRE-PERARD, C., FERRIER-LE BOUEDEC, M., G. BETAIL, P. SOUTEYRAND, and D. CAILLAUD. 1999. Acquired angioedema with C1 inhibitor deficiency: is the distinction between type I and type II still relevant? Dermatology 199: 227.
43. CARUGATI, A., E. PAPPALARDO, L. C. ZINGALE, and M. CICARDI 2001. C1-inhibitor deficiency and angioedema. Mol. Immunol. 38: 161.
44. CICARDI, M., A. BERETTA, M. COLOMBO, D. GIOFFRE, M. CUGNO, and A. AGOSTONI. 1996. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Clin. Exp. Immunol. 106: 475.
45. ALSENZ, J., K. BORK, and M. LOOS. 1987. Autoantibody-mediated acquired deficiency of C1 inhibitor. N. Engl. J. Med. 316: 1360.
46. JACKSON, J., R. B. SIM, K. WHALEY, and C. FEIGHERY. 1989. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema. J. Clin. Invest. 83: 698.
47. MANDLE, R., C. BARON, E. Roux, R. SUNDEL, J. GELFAND, K. AULAK, A. E. DAVIS, F. S. ROSEN, and D. H. BING. 1994. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J. Immunol. 152: 4680.
48. HE, S., S. TSANG, J. NORTH, N. CHOHAN, R. B. SIM, and K. WHALEY. 1996. Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency. J. Immunol. 156: 2009.
49. NUIJENS, J. H., EERENBERG-BELMER, A. J., C. C. HUIJBREGTS, W. O. SCHREUDER, FELTBERSMA, R. J., J. J. ABBINK, L. G. THIJS, and C. E. HACK. 1989. Proteolytic inactivation of plasma C1-inhibitor in sepsis. J. Clin. Invest. 84: 443.
50. HACK, C. E., H. J. VOERMAN, B. EISELE, H. O. KEINECKE, J. H. NUIJENS, A. J. EERENBERG, A. OGILVIE, STRACK VAN SCHIJNDEL, R. J., U. DELVOS, and L. G. THIJS. 1992. C1-esterase inhibitor substitution in sepsis. Lancet 339: 378.
51. CALIEZI, C., W A. WUILLEMIN, S. ZEERLEDER, M. REDONDO, B. EISELE, and C. E. HACK. 2000. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52: 91.